Internet Archive Scholar

Study of the Efficacy of Triple Therapy of Sofosbuvir, Pegylated INFalpha 2a and Ribavirin in Treatment of Chronic Hepatitis C Patients Genotype 4 with High Fibrosis

Alaa Aboud
2017 Open Journal of Gastroenterology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.7 MB)
https://web.archive.org/web/20170923044911/http://file.scirp.org/pdf/OJGas_2017011116194249.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL. The file type is application/pdf.

Purpose: The aim is evaluation of the efficacy of triple therapy of sofosbuvir, pegylated INFalpha 2a and ribavirin in treatment of chronic hepatitis C (CHC) patients genotype 4 who have high fibrosis. Materials and Methods: Fifty HCV patients with high fibrosis (F3 & F4) were included in the study. Results: SVR rate was 54%; non-responders rate was 12% and relapsers rate was 34%. When comparing SVR between F3 group patients and F4 group, it was 88% and 66% respectively, which means that SVR
more » ... higher in the F3 group. Conclusion: Triple therapy including pegylated INFalpha 2a is not an ideal therapy in treatment of CHC patients genotype 4 with cirrhosis because of low sustained virological response rates and high incidence of side effects.
doi:10.4236/ojgas.2017.71002 fatcat:egts7l2ngbcltkudeenj4ya56e
Open Access
Citation

Alaa Aboud. "Study of the Efficacy of Triple Therapy of Sofosbuvir, Pegylated INFalpha 2a and Ribavirin in Treatment of Chronic Hepatitis C Patients Genotype 4 with High Fibrosis." Open Journal of Gastroenterology 07.01 (2017) 5-17